Synthesis of 1-Azabicyclic Systems by Double Cyclization

Mitsuru Oka [a]*, Kunihisa Baba [a], Kensuke Nakamura [b][†], Lulu Dong [c], Hitoshi Hamajima [a], Ryoichi Unno [a] and Yukiharu Matsumoto [a]

[a] Central Research Laboratory, Sanwa Kagaku Kenkyusho, Co., Ltd., 363 Shiosaki, Hokusei-cho, Inabe-gun, Mie 511-0406, Japan
[b] Institute of Medicinal Molecular Design, 5-24-5 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan
[c] Chemistry Department of Harbin Medical University, Harbin, Heilongjiang 150086, China Received September 13, 2002

5-Cyano-1-azabicyclo[3.3.0]octane (1) was prepared in one step from 1,7-dichloro-4-heptanone (4) under mild conditions. The application of this method for the preparation of 5-cyano-4,6-dimethyl-1-azabicy-clo[3.3.0]octane (11) gave two diastereomers in equilibrium. The NMR measurements of 11 and its reduced compound 15 showed that the major isomer is the *cis-exo* form, and the minor isomer is the *trans* form. Molecular orbital calculations indicated that the *cis-exo* form is more stable than the *trans* form, in agreement with the experimental results. Furthermore, 6-cyano-1-azabicyclo[4.3.0]nonane (17) and 1-azabicyclo[4.4.0]decane (19), both including a six-membered ring, were prepared from appropriate haloketones by using this double cyclization method.

J. Heterocyclic Chem., 40, 177 (2003).

Introduction.

1-Aazabicyclo[3.3.0]octane is a useful amine moiety for producing biologically active substances, for example, antiarrhythmic agents, cerebral function activators, and muscarinic M_1 receptor agonists (Figure 1) [1]. 5-Cyano-1-azabicyclo[3.3.0]octane (1) is a useful intermediate for introducing a 1-azabicyclo[3.3.0]octane ring through a conversion of a cyano group to various functional groups [2]. However, the known preparation methods for 1 require many steps, as well as the handling of an unstable intermediate [3,4]. In this paper, we describe a novel preparation method for 1 that avoids these disadvantages [5]. We discuss the stereochemistry involved in the formation of this ring with methyl groups. We also describe the formation of 1-azabicyclic compounds containing a six-membered ring.



Figure 1. Biologically active substances with 1-azabicylco[3.3.0]octane.

Results and Discussion.

The retrosynthesis of **1** is shown in Scheme 1. Compound **1** might be synthesized by double cyclization of 2-amino-5-chloro-2-(3-chloropropyl)pentanenitrile (**2**),



which is an intermediate of the Strecker reaction [6] of 1,7dichloro-4-heptanone (4) [7] *via* imine **3**. Alternatively, double cyclization of **3** can lead to 1-azoniabicyclo-[3.3.0]oct-1(5)-ene chloride (**5**); the known perchlorate **6** [3a] can be transformed to **1** *via* addition of cyanide ion. When we first stirred **4** in MeOH with acetone cyanohydrine (**8**) and ammonia, we obtained a mixture of **1** and 2-(3-chloropropyl)tetrahydrofuran-2-carbonitrile (**7**) (Table 1, entry 1). Compound **7** was formed by transcyanation of **4** prior to imine formation, and subsequent cyclization. When we replaced **8** by the more stable 2-amino-2-methylpropanenitrile (**9**) [8] as a cyanide source, we obtained **1** in 83% yield without the formation of **7** (Table 1, entry 2).

The reaction of **10** [9] with **9** and ammonia in a sealed tube at 50° gave **11** as a mixture of two diasteroisomers in 40% yield. The ¹H NMR spectrum analysis indicated that the major (*cis*) isomer had only one signal peak for the methyl hydrogens at δ 1.25 ppm, and the minor (*trans*) isomer had two signal peaks for the methyl hydrogens at δ



1.14 ppm and δ 1.23 ppm. The observed *cis/trans* ratio was 79:21 (Scheme 2). Furthermore, the fact that the methine protons at the 4- and 6-positions of **11** were replaced with deuterium at room temperature in deuterated methanol indicated that *cis*-**11** and *trans*-**11** are in a thermodynamic equilibrium *via* **12**, **13**, and **14** (Scheme 2). The *ab initio* MO calculations at MP2/6-31G* showed that *cis-exo-***11** is 1.8 kcal mol⁻¹ more stable than *trans-***11**, a finding in accord with the experimental results (Figure 2). Meanwhile, *cis-endo-***11** could not be formed because of the instability caused by the steric repulsion between the methyl groups; the relative energy difference between *cis-exo-***11** and the hypothetical *cis-endo-***11** was calculated as 6.7 kcal mol⁻¹.



Reagents and Conditions: (a) NH_3 (excess), **9** (3 eq.), MeOH in sealed tube, 50°, overnight (40%).

Compound **11** was reduced to generate **15** using LiAlH₄ without changing the ratio of the diastereoisomers. The mixture of diastereoisomers was converted to benzyl carbamates, separated by chromatography on alumina, and hydrogenated with 5% Pd-C to give each isomer of **15** (Scheme 3). The ¹H NMR spectrum showed that the major isomer had one signal peak (δ 1.03 ppm) for the methyl hydrogens, and the protons of the *CH*₂-NH₂ methylene group are magnetically equivalent. The minor isomer





trans-11: -498.509445 (1.8)

Figure 2. Optimized structures and energies (Hartree) of *cis-exo-***11** and *trans-***11** at the MP2/6-31G* level. Numbers in parentheses are relative energies in kcal mol⁻¹.



Reagents and Conditions: (a) LiAlH₄, Et₂O, reflux, 3 hours (78%); (b) CbzCl, NaOH, dioxane/H₂O, room temperature, overnight; (c) chromatography on Al₂O₃; (d) H₂, 5% Pd/C, EtOH, room temperature, overnight (*cis-exo-***15**, 49%; *trans-***15**, 8.9%); (+) NOE correlations observed from NOESY spectra.

showed two signal peaks (δ 0.97 ppm and δ 1.04 ppm) for the methyl hydrogens, and the methylene protons of the *CH*₂-NH₂ group are in this case nonequivalent. These results indicate that the major isomer is in the symmetric *cis* form, while the minor isomer is in the *trans* form. Furthermore, a NOE correlation from the NOESY spectrum of the *cis* isomer was observed between the signals at δ 2.52 ppm, corresponding to the *CH*₂-NH₂ methylene group, and at δ 1.03 ppm, corresponding to the methyl groups; this result indicated the *cis-exo* configuration. In the *trans* isomer, a NOE correlation was observed between the signals (δ 2.50 ppm and δ 2.56 ppm) corresponding to the *CH*₂-NH₂ methylene group and the signal at δ 0.97 ppm, corresponding to the *exo*-methyl group.

The reaction of **16** [10] at 20° for 24 hours with ammonia and **9** gave 6-cyano-1-azabicyclo[4.3.0]nonane (**17**) [11] in 57% yield (Scheme 4); the reaction of **18** [10] gave 6-cyano-1-azabicyclo[4.4.0]decane (**19**) [11] in 21% yield.

In conclusion, we have developed a novel method for preparing 1 by double cyclization of 4. The application of this method to the preparation of 11 gave two diastereoisomers



Reagents and Conditions: (a) NH_3 (excess), **9** (3 eq.), MeOH, room temperature, 24 hours (**17**, 57%; **19**, 21%).

reflecting possible configurations of the methyl groups. The observed ratio of the isomers as determined by NMR measurements is consistent with the relative energies estimated by *ab initio* MO calculations. Furthermore, this reaction was applied to prepare six-five and six-six fused-ring systems in the case of compounds **17** and **19**. The conversion of the nitrile group to various functional groups allows the transformation of bicyclic amine moieties into various biologically active substances. The introduction of a cyanomethyl group [12], an ethoxycarbonylmethyl group [12], and a nitromethyl group [1b] to this ring has been reported by modifications of the presented method. Further applications of this method are expected.

EXPERIMENTAL

Infrared (IR) spectra were obtained on a JASCO FT/IR-8000 or a PERKIN ELMER FTIR 1600, and NMR spectra were obtained using a JEOL JNM-GSX270 spectrometer (270 MHz for ¹H and 68 MHz for ¹³C) or a JEOL JNM-ECP400 (400 MHz for ¹H and 100 MHz for ¹³C) using tetramethylsilane (TMS) as an internal standard. The mass spectra were obtained on a JEOL JMS-DX 300 spectrometer.

Computational Methods.

All of the *ab initio* MO calculations were carried out using the Gaussian98 software package [13]. Geometries were fully optimized at the MP2/6-31G* level.

5-Cyano-1-azabicyclo[3.3.0]octane (1).

To a solution of NH₃ (27 g, 1.6 mol) in MeOH (150 g), **4** (30 g, 0.16 mol) and **9** (41 g, 0.49 mol) were added at 5°. The mixture was stirred at 20° for 24 hours, and concentrated. The residue was dissolved in 5 *N* NaOH aqueous solution, and extracted with CH₂Cl₂. The organic layer was dried over Na₂SO₄, concentrated, and distilled to give **1** (18 g, 81%) as a colorless oil, bp 91-94° (4.4 mmHg) [Lit. [3a] 93-94° (5 mmHg)]; ¹H NMR (CDCl₃): δ 1.76-2.10 (m, 6H, H3, H7, two protons of H4 and H6), 2.27-2.38 (m, 2H, two protons of H4 and H6), 2.53-2.63 and 3.07-3.25 (m, 4H, H2, H8); ¹³C NMR (CDCl₃): δ 26.40 (C3, C7), 38.45 (C4, C6), 55.33 (C2, C8), 67.09 (C5), 124.56 (CN); IR (neat): 2969, 2870 (C-H), 2232 (CN) cm⁻¹; HRMS (EI): calcd for C₈H₁₂N₂ (M⁺) 136.1000, found 136.0982.

2-(3-Chloropropyl)tetrahydrofuran-2-carbonitrile (7).

To a solution of NH_3 (0.60 g, 35 mmol) in MeOH (5 mL), **4** (0.50 g, 2.7 mmol) and **8** (2.3 g, 27 mmol) were added at 5°. The mixture was stirred at 20° for 24 hours, and concentrated. The

residue was dissolved in 1 *N* aqueous solution, and extracted with CH₂Cl₂. The organic layers were combined, dried over Na₂SO₄, concentrated, and purified by chromatography on silica (n-hexane/EtOAc) to give **7** (39 mg, 8.2%) as a colorless oil, ¹H NMR (CDCl₃): δ 1.86-2.46 (m, 8H, H3, H4, H2', H1'), 3.58-3.65 (m, 2H, H3'), 4.01 (t, *J* = 6.8 Hz, 2H, H5); ¹³C NMR (CDCl₃): δ 24.78 and 27.88 (C4, C2'), 35.88 and 37.52 (C3, C1'), 44.22 (C3'), 68.83 (C5), 78.92 (C2), 120.46 (CN); IR (neat): 2963, 2882 (C-H), 2232 (CN) cm⁻¹; HRMS (EI): calcd for C₈H₁₂ClNO (M⁺, ³⁵Cl) 173.0607, found 173.0596.

5-Cyano-4,6-dimethyl-1-azabicyclo[3.3.0]octane (11).

To a solution of **10** (1.0 g, 4.7 mmol) and **9** (1.2 g, 14 mmol) in MeOH (1 mL), NH₃ (1.8 g, 0.11 mol) was introduced at -50°. The mixture was stirred in a sealed tube at 50-60° overnight. After cooling, the resulting mixture was poured into Et₂O, and a precipitate was filtered off. The filtrate was concentrated, and purified by chromatography on alumina (n-hexane/EtOAc 50:1) to give 11 (0.31 g, 40%, the ratio of the isomers was 79:21) as a colorless oil, ¹H NMR (CDCl₃): major isomer δ 1.25 (d, J = 6.4Hz, 6H, CH₃x2), 1.84-2.13 (m, 6H, H3, H4, H6, H7), 2.47-2.56 and 3.21-3.28 (m, 4H, H2, H8); minor isomer δ 1.14 (d, J = 7.3 Hz, 3H, CH₃), 1.23 (d, J = 5.9 Hz, 3H, CH₃), 1.46-1.60 and 1.88-2.10 (m, 5H, H3, H7, one proton of H4 and H6), 2.41-2.69 (m, 3H, one proton of H4 and H6, two protons of H2 and H8), 3.04-3.15 (m, 2H, two protons of H2 and H8); ¹³C NMR (CDCl₂): major isomer δ 15.89 (CH₃), 36.53 (C3, C7), 43.50 (C4, C6), 54.53 (C2, C8), 77.79 (C5), 119.93 (CN); minor isomer δ 13.89, 15.75, 32.36, 35.22, 37.62, 43.06, 53.83, 55.33, 74.23, 122.53; IR (neat): 2964, 2926 (C-H), 2219 (CN) cm-1; HRMS (EI): calcd for C₁₀H₁₆N₂ (M⁺) 164.1313, found 164.1289.

5-Aminomethyl-4,6-dimethyl-1-azabicyclo[3.3.0]octane (15).

A solution of 11 (0.38 g, 2.3 mmol) in ether (3 mL) was added dropwise to a suspension of LiAlH₄ (0.26 g, 6.8 mmol) in ether (7 mL) under reflux. The mixture was refluxed for 3 hours, quenched with water (0.26 mL), 15% NaOH (0.26 mL) and water (0.79 mL). The white precipitate was filtered off, and the filtrate was concentrated to give a mixture of two diastereoisomers of 15 (0.30 g, the ratio of the isomers was 77:23) as a colorless oil. To a solution of 15 (0.30 g, 1.8 mmol) in dioxane (0.5 mL) and 5 N NaOH (0.54 mL, 2.7 mmol), CbzCl (0.40 g, 2.3 mmol) was added at 4°. The solution was stirred overnight at room temperature, and extracted with EtOAc. The organic layer was dried over Na₂SO₄ and concentrated. The resulting mixture was separated into a major isomer (0.28 g) and a minor isomer (0.053 g) by chromatography on alumina (n-hexane/EtOAc). Each solution of the isomers in EtOH was stirred under H₂ with 5% Pd-C (20 wt%) overnight at room temperature, and filtered. The filtrates were concentrated to give *cis-exo-***15** (0.15 g, 49%) and *trans-***15** (0.027 g, 8.9%) as colorless oils, respectively. *cis-exo-***15**: ¹H NMR (CDCl₃): δ 1.03 (d, J = 7.0 Hz, 6H, CH₃x2), 1.73-2.03 (m, 6H, H3, H4, H6, H7), 2.52 (s, 2H, CH₂NH₂), 2.49-2.55 and 3.14-3.18 (m, 4H, H2, H8); ¹³C NMR (CDCl₃): δ 14.40 (CH₃), 37.51 (C3, C7), 43.63 (CH₂NH₂), 45.13 (C4, C6), 55.27 (C2, C8), 75.14 (C5); IR (neat): 3329 (N-H), 2953, 2876 (C-H) cm⁻¹; HRMS (EI): calcd for C₉H₁₆N (M-CH₂NH₂)⁺ 138.1283, found 138.1278. *trans*-15: ¹H NMR (CDCl₃): δ 0.97 (d, J = 7.0 Hz, 3H, exo-CH₃), 1.04 (d, J = 7.0 Hz, 3H, endo-CH₃), 1.46-1.96 (m, 4H, H3, H7), 1.80-1.96 (m, 1H, endo-CH), 2.14-2.24 (m, 1H, exo-CH), 2.50 and 2.56 (d, J = 12.5 Hz, 2H, CH₂NH₂), 2.37-2.43,

2.56-2.60, 2.75-2.82 and 3.11-3.15 (m, 4H, H2, H8); ¹³C NMR (CDCl₃): δ 13.68 (s, 3H, *exo*-CH₃), 14.05 (s, 3H, *endo*-CH₃), 32.04 and 34.19 (C3, C7), 37.39 and 37.82 (C4, C6), 44.75 (CH₂NH₂), 54.63 and 55.34 (C2, C8), 74.55 (C5); IR (neat): 3364 (N-H), 2957, 2875 (C-H) cm⁻¹; HRMS (EI): calcd for C₉H₁₆N (M-CH₂NH₂)⁺ 138.1283, found 138.1294.

6-Cyano-1-azabicyclo[4.3.0]nonane (17).

By using a similar procedure as that described for **1**, **17** was prepared from **16** (0.50 g, 1.7 mmol) and isolated after chromatography on alumina (*n*-hexane/EtOAc) as a colorless oil (0.15 g, 57%), ¹H NMR (CDCl₃): δ 1.38-1.90 and 2.34-2.53 (m, 10H, H3, H4, H5, H7, H8), 2.08-2.27 and 2.92-3.01 (m, 4H, H2, H9); ¹³C NMR (CDCl₃): δ 19.28 (C8), 21.55 (C4), 24.51 (C3), 34.07 and 36.78 (C5 and C7), 48.01 and 51.11 (C2 and C9), 63.86 (C6), 118.71 (CN); IR (neat): 2938 (C-H), 2214 (CN) cm⁻¹; HRMS (EI): calcd for C₁₀H₁₆N₂ (M⁺) 150.1157, found 150.1148.

6-Cyano-1-azabicyclo[4.4.0]decane (19).

By using the same procedure as described for **17**, **19** (34 mg, 21%) was prepared from **18** (300 mg, 1.0 mmol) as a colorless oil, ¹H NMR (CDCl₃): δ 1.48-1.87 (m, 12H, H3, H4, H5, H7, H8, H9), 2.33-2.40 and 2.65-2.69 (m, 4H, H2, H10); ¹³C NMR (CDCl₃): δ 21.42 (C4, C8), 25.01 (C3, C9), 36.89 (C5, C7), 52.43 (C2, C10), 64.34 (C6), 118.04 (CN); IR (neat): 2939 (C-H), 2215 (CN) cm⁻¹; HRMS (EI): calcd for C₁₀H₁₆N₂ (M⁺) 164.1313, found 164.1312.

Acknowledgment.

The authors thank Professor Masayuki Shibuya (Tokushima University) for his helpful suggestions.

REFERENCES AND NOTES

* Author for correspondence. E-mail: m_oka@mb6.skk-net.com

[†] Present address: Graduate School of Information Science, Nara Institute of Science and Technology, Ikoma-shi, Nara 630-0101, Japan.

[1a] S. Miyano, K. Sumoto, F. Satoh, K. Shima, M. Hayashimatsu, M. Morita, K. Aisaka and T. Noguchi, *J. Med. Chem.*, 28, 714 (1985);
[b] M. Oka, Y. Matsumoto, K. Hirooka and T. Suzuki, *Chem. Pharm. Bull.*, 48, 1121 (2000);
[c] T. Suzuki, M. Oka, K. Maeda, K. Furusawa, H. Uesaka and T. Kataoka, *Chem. Pharm. Bull.*, 47, 28 (1999).

[2] S. Miyano, O. Yamashita, K. Sumoto, K. Shima, M. Hayashimatsu and F. Satoh, *J. Heterocyclic Chem.*, **24**, 47 (1987).

[3a] S. Miyano, T. Somehara, M. Nakao and K. Sumoto, *Synthesis*, 701 (1978); [b] S. Miyano, S. Fujii, O. Yamashita, N. Toraishi and K. Sumoto, *J. Heterocyclic Chem.*, **19**, 1465 (1982).

[4] Y. Arata, K. Tanaka, S. Yoshifuji and S. Kanatomo, *Chem. Pharm. Bull.*, **27**, 981 (1979).

[5] Preliminary report: M. Oka, Y. Matsumoto and R. Unno, *Heterocycles*, **45**, 1447 (1997).

[6] N. Zelinsky and G. Stadnikoff, *Chem. Ber.*, **39**, 1722 (1906).

[7] H. Hart and O. E. Curtis, Jr., J. Am. Chem. Soc., 78, 112 (1956).

[8] R. A. Jacobson, J. Am. Chem. Soc., 68, 2628 (1946).

[9] G. Böhrer and R. Knorr, *Tetrahedron Lett.*, **25**, 3675 (1984).

[10a] R. E. Ireland and D. Häbich, *Chem. Ber.*, **114**, 1418 (1981); [b] H. Stetter and H. Rauhut, *Chem. Ber.*, **91**, 2543 (1958).

[11] N. J. Leonard and A. S. Hay, J. Am. Chem. Soc., 78, 1984 (1956).

[12] M. Oka, K. Baba, T. Suzuki and Y. Matsumoto, *Heterocycles*, **45**, 2317 (1997).

[13] M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, V. G. Zakrzewski, J. A. Montgomery, R. E. Stratmann, Jr., J. C. Burant, S, Dapprich, J. M. Millam, A. D. Daniels, K. N. Kudin, M. C. Strain, O. Farkas, J. Tomasi, V. Barone, M. Cossi, R. Cammi, B. Mennucci, C. Pomelli, C. Adamo, S. Clifford, J. Ochterski, G. A. Petersson, P. Y. Ayala, Q. Cui, K. Morokuma, D. K. Malick, A. D. Rabuck, K. Raghavachari, J. B. Foresman, J. Cioslowski, J. V. Ortiz, B. B. Stefanov, G. Liu, A. Liashenko, P. Piskorz, I. Komaromi, R. Gomperts, R. L. Martin, D. J. Fox, T. Keith, M. A. Al-Laham, C. Y. Peng, A. Nanayakkara, C. Gonzalez, M. Challacombe, P. M. W. Gill, B. Johnson, W. Chen, M. W. Wong, J. L. Andres, C. Gonzalez, M. Head-Gordon, E. S. Replogle and J. A. Pople, *Gaussian 98*, Revision A.9; Gaussian, Inc., Pittsburgh, PA, 1998.